Oncternal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncternal Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11078
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncternal Therapeutics Inc (Oncternal) is a clinical-stage oncology company that develops therapies for rare and common cancers. The company’s pipeline compounds include cirmtuzumab and TK216. Its compounds are primarily focused on exciting targets which are uniquely expressed within cancer cells. Oncternal addresses different medical challenges from antibodies and antibody-drug conjugates to small molecules and chimeric antigen receptor T-cells. The company develops clinical-stage products with common regulatory and development strategies. It has academic collaborations to identify and develop novel research approaches. Oncternal is headquartered in San Diego, California, the US.

Oncternal Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Partnerships 20
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 20
Merger 21
Oncternal Therapeutics Merges with Tokalas 21
Licensing Agreements 22
Oncternal Therapeutics Enters into Licensing Agreement with University of California 22
Oncternal Therapeutics Inc – Key Competitors 23
Oncternal Therapeutics Inc – Key Employees 24
Oncternal Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Apr 03, 2018: Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncternal Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncternal Therapeutics Raises Additional USD6.6 Million in Venture Financing 10
Oncternal Therapeutics Raises USD18.4 Million in Series B Financing 11
Oncternal Therapeutics Raises Additional USD5.2 Million in Venture Financing 12
Oncternal Therapeutics Raises Additional USD2.4 Million in Venture Financing 13
Oncternal Therapeutics Raises USD0.2 Million in Venture Financing 14
Oncternal Therapeutics Raises USD13 Million in Venture Financing 15
Oncternal Therapeutics Raises Additional USD0.6 Million in Venture Financing 16
Oncternal Therapeutics Raises USD3.2 Million in Venture Financing 17
Tokalas Raises USD3.2 Million in Venture Financing 18
Tokalas Raises USD3.1 Million in Venture Financing 19
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 20
Oncternal Therapeutics Merges with Tokalas 21
Oncternal Therapeutics Enters into Licensing Agreement with University of California 22
Oncternal Therapeutics Inc, Key Competitors 23
Oncternal Therapeutics Inc, Key Employees 24

List of Figures
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncternal Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oncternal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Teleplan International NV:企業の戦略的SWOT分析
    Teleplan International NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ImmusanT Inc-医療機器分野:企業M&A・提携分析
    Summary ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are al …
  • Societe Electrique de l’Our SA:企業の戦略的SWOT分析
    Societe Electrique de l'Our SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • PTC Inc (PTC):企業の財務・戦略的SWOT分析
    PTC Inc (PTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Riyad Bank:企業の戦略・SWOT・財務情報
    Riyad Bank - Strategy, SWOT and Corporate Finance Report Summary Riyad Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • M3 Biotechnology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary M3 Biotechnology Inc (M3 Biotech) is a clinical stage biotech company that focuses on regenerative medicine. The company is developing clinical programs for the treatment of Alzheimer, MS, Parkinson and Alzheimerdisease (oral) among others. It utilizes discovery platform and develops small m …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Raley’s Family of Fine Stores:企業の戦略的SWOT分析
    Raley's Family of Fine Stores - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Ygm Trading Ltd.
    Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Volta River Authority:電力:M&Aディール及び事業提携情報
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. It produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. The authority procures energy from Takoradi International Company Ltd; an …
  • Staatsolie Maatschappij Suriname NV:企業の戦略的SWOT分析
    Staatsolie Maatschappij Suriname NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • MYR Group Inc (MYRG):企業の財務・戦略的SWOT分析
    Summary MYR Group Inc (MYR Group) is an electrical contractor that provides specialty contracting services for industrial, commercial, and electrical infrastructure markets. The company operates substations, transmission lines, and distribution systems. It offers services such as distribution constr …
  • Silmag SA:企業の製品パイプライン分析2018
    Summary Silmag SA (Silmag) is a manufacturer of biomedical products. The company offers products for vascular access, drainage, digestive tract, airway and urinary system. Its products include catheters, drainage tube, occlusion and identification tape, airway tube, double pigtail ureteral stent, cl …
  • Tessa Therapeutics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Tessa Therapeutics Pte Ltd (Tessa Therapeutics) is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products …
  • Equinor ASA (EQNR):企業の財務・戦略的SWOT分析
    Equinor ASA (EQNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Entertainment One Ltd.:企業の戦略・SWOT・財務分析
    Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report Summary Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • StealthGas Inc (GASS):企業の財務・戦略的SWOT分析
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …
  • Murphy USA Inc:企業の戦略・SWOT・財務分析
    Murphy USA Inc - Strategy, SWOT and Corporate Finance Report Summary Murphy USA Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Porton Fine Chemicals Ltd (300363):製薬・医療:M&Aディール及び事業提携情報
    Summary Porton Fine Chemicals Ltd (Porton) is a supplier of custom drug intermediates and active pharmaceutical ingredients. The company provides custom and contract chemical development, and contract manufacturing services. It provides products such as reactive reagents, chiral chromatography produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆